High tissue PD‐L1 expression, microsatellite instability‐high (MSI‐H), or tumor mutational burden (TMB) are biomarkers that, when present before treatment in certain tumor types, increase the likelihood of immunotherapy clinical benefit [6, 7, 8, 9]. This evidence concerns the gene CD274 and neoplasm.